Table 1.

List of approved checkpoint inhibitors used in bladder cancer treatment.

Compound	Trade Name	Company	Target	Date of Approval	Clinical Trial Leading to Approval
Atezolizumab	Tecentriq	Genentech	PD-L1	2016	IMVigor210 [48]
Avelumab	Bavencio	Merck	PD-L1	2017	JAVELIN [49]
Durvalumab	Imfinzi	AstraZeneca	PD-L1	2017	Study 1108 [50]
Nivolumab	Opdivo	Bristol-Meyers Squibb	PD-1	2017	CheckMate 275 [51]
Pembrolizumab	Keytruda	Merck	PD-1	2019	KEYNOTE-057 [52]
Ipilimumab	Yervoy	Bristol-Meyers Squibb	CTLA-4	2019	NCT01524991 [53]

PD-L1: programmed death ligand 1; PD-1: programmed cell death protein 1; CTLA-4: Cytotoxic T lymphocyte-associated protein 4.